Pyrazole compounds useful as protein kinase inhibitors

US7390815B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Robert J. Davies · Arlington, US
• David Bebbington · Newbury, GB
• Ronald Knegtel · Abingdon, GB
• Marion W. Wannamaker · Sharonville, US
• Pan Li · Lexington, US
• Cornelia Forster · Bensalem, US
• Albert Pierce · Cambridge, US

Key dates

• Filing date: Oct 23, 2003
• Grant date: Jun 24, 2008
• Expiry date: Oct 23, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention describes novel pyrazole compounds of formula II:wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, and R2, R2′, Rx, and Ry are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R2 and R2′ are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and Rx and Ry are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.